spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

High performance range of insulated shipping systems

Laminar Medica


Laminar Medica’s Chilltherm® Global range of high performance insulated shipping systems, from 4 to 1130 litres product volume, are designed to offer optimal thermal protection for pharmaceutical products when exposed to extreme climates from -20°C to +40°C.

These shipping systems are pre-qualified to maintain payload integrity between +2°C and +8°C for transit durations of up to 120 hours. Real live data profiles have been used to give customers confidence that the quality and efficacy of their payloads will not be compromised during even the most demanding external temperatures. Cross hemisphere profile testing makes it ideal for clients making transcontinental shipments.

With only three sizes of cool packs used across the range and a common bill of materials for summer and winter pack outs the impact to warehousing and handling is minimised.

phone 44 (0)14 4282 8664
email enquiries@laminarmedica.co.uk
web www.laminarmedica.com
email Unit 4 Tring Industrial Estate, Icknield Way, Tring, Hertfordshire, HP23 4JX
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Intelsius Discusses In-Country Distribution At Iqpc Cool Chain Europe

Intelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, based in York, is directing its focus on in-country distribution at the 14th Annual IQPC Cool Chain Europe, held in Frankfurt, Germany, 26-29 January 2015.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

Industry Events

Central Labs

24-25 February 2015, Park Plaza Victoria, London

Packed full of informative case studies and industry insight, the 12th Annual: Central, Biomarker and Specialty Labs Summit will take place 24-25 Feb. 2015 in London.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement